 |
Products |  |
Diseases | | Products |
|
Trials |  |
News |  |
- || IBIO123 / Immune Biosolutions
P1/2 data, Journal: Safety and efficacy of inhaled IBIO123 for mild-to-moderate COVID-19: a randomised, double-blind, dose-ascending, placebo-controlled, phase 1/2 trial. (Pubmed Central) - Dec 25, 2023
P1/2
Despite the lack of significant reduction of viral load at day 5, treatment with IBIO123 resulted in a higher proportion of participants with complete resolution of respiratory symptoms at day 6. This study supports further clinical research on inhaled monoclonal antibodies in COVID-19 and respiratory diseases in general.
- ||| IBIO123 / Immune Biosolutions
Trial completion: Phase 1&2 Study to Evaluate the Safety & Efficacy of Inhaled IBIO123 in Severe COVID-19 Illness (clinicaltrials.gov) - Sep 13, 2023
P1/2, N=123, Completed, Sponsor: Immune Biosolutions Inc
This study supports further clinical research on inhaled monoclonal antibodies in COVID-19 and respiratory diseases in general. Active, not recruiting --> Completed
- || IBIO123 / Immune Biosolutions
Enrollment closed: Phase 1&2 Study to Evaluate the Safety & Efficacy of Inhaled IBIO123 in Severe COVID-19 Illness (clinicaltrials.gov) - Jun 15, 2023
P1/2, N=123, Active, not recruiting, Sponsor: Immune Biosolutions Inc
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- ||| IBIO123 / Immune Biosolutions
Trial completion: Study in Adults to Assess the Safety and Efficacy of Inhaled IBIO123, for Post-exposure Prophylaxis of COVID-19 (clinicaltrials.gov) - May 22, 2023
P2, N=200, Completed, Sponsor: Immune Biosolutions Inc
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- || IBIO123 / Immune Biosolutions
Enrollment closed: Study in Adults to Assess the Safety and Efficacy of Inhaled IBIO123, for Post-exposure Prophylaxis of COVID-19 (clinicaltrials.gov) - May 9, 2023
P2, N=200, Active, not recruiting, Sponsor: Immune Biosolutions Inc
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- || IBIO123 / Immune Biosolutions
Trial completion date, Trial primary completion date: Phase 1&2 Study to Evaluate the Safety & Efficacy of Inhaled IBIO123 in Severe COVID-19 Illness (clinicaltrials.gov) - May 1, 2023
P1/2, N=166, Recruiting, Sponsor: Immune Biosolutions Inc
Recruiting --> Active, not recruiting Trial completion date: Mar 2023 --> Jun 2023 | Trial primary completion date: Mar 2023 --> Jun 2023
- ||| IBIO123 / Immune Biosolutions
Enrollment open, Enrollment change: Study in Adults to Assess the Safety and Efficacy of Inhaled IBIO123, for Post-exposure Prophylaxis of COVID-19 (clinicaltrials.gov) - May 1, 2023
P2, N=200, Recruiting, Sponsor: Immune Biosolutions Inc
Trial completion date: Mar 2023 --> Jun 2023 | Trial primary completion date: Mar 2023 --> Jun 2023 Not yet recruiting --> Recruiting | N=140 --> 200
- ||| IBIO123 / Immune Biosolutions
Trial completion: Phase 1/2 Study to Evaluate the Efficacy and Safety of Inhaled IBIO123 in Participants With Mild to Moderate COVID-19 Illness (clinicaltrials.gov) - May 1, 2023
P1/2, N=162, Completed, Sponsor: Immune Biosolutions Inc
Not yet recruiting --> Recruiting | N=140 --> 200 Recruiting --> Completed
- |||| IBIO123 / Immune Biosolutions
New P2 trial: Study in Adults to Assess the Safety and Efficacy of Inhaled IBIO123, for Post-exposure Prophylaxis of COVID-19 (clinicaltrials.gov) - Dec 6, 2022
P2, N=140, Not yet recruiting, Sponsor: Immune Biosolutions Inc
- || IBIO123 / Immune Biosolutions
Trial primary completion date: Phase 1/2 Study to Evaluate the Efficacy and Safety of Inhaled IBIO123 in Participants With Mild to Moderate COVID-19 Illness (clinicaltrials.gov) - Dec 5, 2022
P1/2, N=224, Recruiting, Sponsor: Immune Biosolutions Inc
Recruiting --> Completed Trial primary completion date: Sep 2022 --> Jan 2023
- || IBIO123 / Immune Biosolutions
Trial completion date, Trial primary completion date: Phase 1&2 Study to Evaluate the Safety & Efficacy of Inhaled IBIO123 in Severe COVID-19 Illness (clinicaltrials.gov) - Dec 5, 2022
P1/2, N=216, Recruiting, Sponsor: Immune Biosolutions Inc
Trial primary completion date: Sep 2022 --> Jan 2023 Trial completion date: Nov 2022 --> Mar 2023 | Trial primary completion date: Sep 2022 --> Mar 2023
- | IBIO123 / Immune Biosolutions
New P1/2 trial: Phase 1&2 Study to Evaluate the Safety & Efficacy of Inhaled IBIO123 in Severe COVID-19 Illness (clinicaltrials.gov) - Mar 31, 2022
P1/2, N=216, Recruiting, Sponsor: Immune Biosolutions Inc
- | IBIO123 / Immune Biosolutions
New P1/2 trial: Phase 1/2 Study to Evaluate the Efficacy and Safety of Inhaled IBIO123 in Participants With Mild to Moderate COVID-19 Illness (clinicaltrials.gov) - Mar 27, 2022
P1/2, N=224, Recruiting, Sponsor: Immune Biosolutions Inc